Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-3537.73%
operating margin TTM
-3767.07%
revenue TTM
150.09 Million
revenue per share TTM
3.87$
valuation ratios | |
|---|---|
| pe ratio | -1.75 |
| peg ratio | 0.03 |
| price to book ratio | 1.26 |
| price to sales ratio | 57.49 |
| enterprise value multiple | -1.94 |
| price fair value | 1.26 |
profitability ratios | |
|---|---|
| gross profit margin | -754.72% |
| operating profit margin | -3767.07% |
| pretax profit margin | -3520.25% |
| net profit margin | -3537.73% |
| return on assets | -55.47% |
| return on equity | -57.61% |
| return on capital employed | -63.61% |
liquidity ratios | |
|---|---|
| current ratio | 10.89 |
| quick ratio | 10.89 |
| cash ratio | 4.65 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 63.56 |
| days of payables outstanding | 34.14 |
| cash conversion cycle | 29.42 |
| receivables turnover | 5.74 |
| payables turnover | 10.69 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.16 |
| debt equity ratio | 0.21 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.17 |
| interest coverage | 0.00 |
| cash flow to debt ratio | -2.77 |
cash flow ratios | |
|---|---|
| free cash flow per share | -3.18 |
| cash per share | 5.28 |
| operating cash flow per share | -3.19 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -2.77 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | -416.95 |
Frequently Asked Questions
When was the last time Entrada Therapeutics, Inc. (NASDAQ:TRDA) reported earnings?
Entrada Therapeutics, Inc. (TRDA) published its most recent earnings results on 05-08-2026.
What is Entrada Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Entrada Therapeutics, Inc. (NASDAQ:TRDA)'s trailing twelve months ROE is -57.61%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Entrada Therapeutics, Inc. (TRDA) currently has a ROA of -55.47%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did TRDA's net profit margin stand at?
TRDA reported a profit margin of -3537.73% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is TRDA's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 10.89 in the most recent quarter. The quick ratio stood at 10.89, with a Debt/Eq ratio of 0.21.